Myovant Sciences Submits New Drug Application (NDA) to the FDA for Once-Daily, Oral Relugolix for the Treatment of Men with Advanced Prostate Cancer
Positive Phase 3 results with 96.7% response rate in men with advanced prostate cancer form the basis of the submissionMyovant […]